Author

Catherine McNamara Page 3

Catherine McNamara, PharmD, BCPS, is a clinical pharmacogenomics specialist at an academic medical center in Boulder, Colorado. She directs a clinical testing service focused on gene-based dosing and investigates how variations in CYP enzymes affect drug response and patient toxicity. McNamara received her PhD in pharmaceutical sciences from the University of California, San Francisco, and she contributes to Biology Insights on medication science.

CKD-510 for CMT: Mechanism, Trials, and Future Outlook Drugs
CYP2C19 Ultrarapid Metabolizer: How It Affects Medications Genetics
What Is Conolidine and How Does It Relieve Pain?Drugs
Hydroxyurea’s Mechanism of Action for Sickle Cell Disease Drugs
What Is a USP1 Inhibitor and How Does It Work?Drugs
Dalfampridine MOA: How It Works for Multiple Sclerosis Drugs
How Tacrolimus Metabolism Works in the Body Drugs
What Is a CYP1A2 Ultrarapid Metabolizer?Genetics
The CYP2D6 Enzyme: How It Metabolizes Common Drugs Genetics
What Is CYP3A4 Metabolism and How Does It Work?Biology
What Is CYP Activity and Why Does It Matter?Biology
Concurrent Use of Fluconazole and Ibuprofen: Mechanisms and Clinical Implications Drugs
Renal Impairment: Pharmacokinetics and Dosage Adjustments Drugs
DNMT Inhibitors: Critical Advances for Disease Treatment Drugs
Levofloxacin: Pharmacokinetics, Stability, and Formulation Impact Drugs
Pharmacokinetics and Dosage in Hypoalbuminemia Treatment Drugs
Lisinopril for Black People: Key Mechanisms and Variation Drugs
Rapalink-1: Brain-Specific mTOR Inhibition Potential Drugs
Target Identification in Drug Discovery: Current Strategies Drugs